Crossfire Oncology Holding B.V.
Records under this name other than patents Crossfire Oncology Holding B.V. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Showing 1 to 5 of 5 · Back to Crossfire Oncology Holding B.V.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US RE48,974 | (5,6-Dihydro)pyrimido[4,5-e]indolizines Formerly held In force · USPTO record | In force | USPTO record | |
| US RE50,082 | (5,6-dihydro)pyrimido[4,5-e]indolizines Formerly held In force · USPTO record | In force | USPTO record | |
| US 12,054,784 | Prognostic Biomarkers for TTK Inhibitor Chemotherapy Formerly held In force · High confidence | In force | High confidence | |
| US 11,208,696 | Prognostic Biomarkers for TTK Inhibitor Chemotherapy Formerly held In force · High confidence | In force | High confidence | |
| US 9,856,258 | (5,6-dihydro)pyrimido[4,5-E]indolizines Formerly held Surrendered on reissue Surrendered on reissue Mar 15, 2022 · USPTO record | Surrendered on reissue | Surrendered on reissue Mar 15, 2022 | USPTO record |